Evidence map›Paper›PMID 36128931›Full record

ArticleHistology and histopathology2023

The role of claudin-6 in chromophobe renal cell carcinoma.

Franziska Erlmeier, Stefanie Zschäbitz, Marie Mikuteit, Michael Autenrieth, Wilko Weichert, Arndt Hartmann, Sandra Steffens

Abstract read
PubMed Publisher
In one paragraph

Article in Histology and histopathology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 1 country.

Franziska ErlmeierInstitute of Pathology, University Hospital of Erlangen, Erlangen, Germany. f.erlmeier@icloud.com.
Stefanie ZschäbitzDepartment of Medical Oncology, National Center of Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany.
Marie MikuteitDepartment for Rheumatology and Immunology, Hannover Medical School, Hannover, Germany.
Michael AutenriethDepartment of Urology, Technical University of Munich, Klinikum rechts der Isar, Munich, Germany.
Wilko WeichertInstitute for Pathology and Pathological Anatomy, Technical University Munich, Munich, Germany.
Arndt HartmannInstitute of Pathology, University Hospital of Erlangen, Erlangen, Germany.
Sandra SteffensDepartment for Rheumatology and Immunology, Hannover Medical School, Hannover, Germany.
Medizinische Hochschule Hannover · DEUniversitätsklinikum Erlangen · DEGerman Cancer Society · DEHeidelberg University · DEKlinikum rechts der Isar · DE

Funding

Deutsche Forschungsgemeinschaft (DFG) GZ:ER 795/1-1
6 · The paper itself

Abstract

backgroundThe prognostic value of Claudin-6 (CLDN6) in non clear cell renal cell carcinoma (RCC) is still unclear.

aimTo evaluate the prognostic impact of CLDN6 expression in a large cohort of chromophobe RCC (chRCC). MATERIAL AND

methodsPatients who underwent renal surgery due to chRCC were recruited. Clinical data were retrospectively evaluated. Tumor specimens were analyzed for CLDN6 expression by immunohistochemistry.

results81 chRCC patients were eligible for analysis, thereof 10 (12.3%) patients were positive for CLDN6. No significant associations were found for CLDN6 expression and clinical attributes in patients with chRCC. Kaplan-Meier analysis revealed no differences in overall survival (OS) for patients with CLDN6⁻ compared to CLDN6⁺ tumors (87.0% versus 62.5%; p=0.174).

conclusionIn chRCC CLDN6 expression is not associated with parameters of aggressiveness or survival. Due to the rare incidence of chRCC further studies with larger cohorts are warranted.

Indexed as

Carcinoma, Renal CellKidney NeoplasmsBiomarkers, TumorClaudinsHumansPrognosisRetrospective StudiesBiomarkers, Tumorclaudin 6Claudins

Identifiers

PMID36128931
OpenAlexW4297874888

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.